INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in UroGen Pharma Ltd. of Class Action Lawsuit And Upcoming Deadlines – URGN
NEW YORK CITY, NY / ACCESS Newswire / July 3, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ:URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are […]